Question 1

What is myelofibrosis (MF)?

Accepted Answer

Myelofibrosis is a rare bone marrow disorder in which scar tissue (fibrosis) replaces normal marrow, reducing the body's ability to produce healthy blood cells. It is classified as a type of chronic blood cancer, specifically a myeloproliferative neoplasm.
Details from NCBI Bookshelf – StatPearls (2023)

Question 2

What causes myelofibrosis?

Accepted Answer

MF is often driven by mutations in blood-forming stem cells—commonly in JAK2, CALR, or MPL genes. These mutations disrupt normal signaling and lead to bone marrow fibrosis.
Details from PMC NCBI (Tefferi A., 2022)

Question 3

What are the symptoms of myelofibrosis?

Accepted Answer

Common symptoms include fatigue, night sweats, enlarged spleen (splenomegaly), bone pain, easy bruising, weight loss, and anemia. Some individuals may remain symptom-free in early stages.

Question 4

Is myelofibrosis curable or reversible?

Accepted Answer

There is no known cure for most cases of myelofibrosis. However, treatments like JAK inhibitors and, in some cases, stem cell transplantation may significantly reduce symptoms or induce remission in select patients.

Question 5

Can myelofibrosis go into remission?

Accepted Answer

Yes, remission is possible, especially after a successful stem cell transplant. Some patients also experience partial remission with targeted therapies, though the disease may eventually progress.

Question 6

Can myelofibrosis lead to leukemia?

Accepted Answer

In some cases, myelofibrosis can progress to acute myeloid leukemia (AML), especially in advanced stages. This transformation is referred to as “blast phase” or “leukemic transformation.”

Question 7

What is the life expectancy with myelofibrosis?

Accepted Answer

Life expectancy varies widely. Some individuals live for many years with minimal symptoms, while others may have a more aggressive disease. Factors like age, genetic mutations, and blood counts affect prognosis.

Question 8

Why does myelofibrosis cause splenomegaly?

Accepted Answer

As marrow function declines, blood production shifts to the spleen and liver (extramedullary hematopoiesis), causing enlargement—most notably splenomegaly in approximately 90% of patients.
Details from MedlinePlus Genetics (NIH, 2014)

Question 9

What treatments are available for myelofibrosis?

Accepted Answer

Treatments may include JAK inhibitors (like ruxolitinib), blood transfusions, medications to manage symptoms, and bone marrow transplants. Therapy is tailored based on age, symptoms, and disease stage.

Question 10

Who treats myelofibrosis?

Accepted Answer

Hematologists or oncologists-especially those specializing in blood cancers-are typically responsible for diagnosing and managing myelofibrosis. Care may also involve transplant specialists and palliative teams.

Myelofibrosis Medications